# Cannabis News and Regulatory Roundup: Cannabis use and route-specific administrati… > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-news-and-regulatory-roundup-cannabis-use-and-route-specific-adm-sep-2026/ > **Published:** 2026-09-27T19:27:20-04:00 | **Last Modified / Clinically Audited:** 2026-10-01T12:32:57-04:00 > **Clinical Summary:** cannabis news digest: CED Clinic analysis of 3 recent cannabis policy, science, and regulatory developments with Dr. Benjamin Caplan. --- CED Clinical Relevance #65 Verified Overview Curated multi-source overview preserving 3 verified developments. Clinical Insight | CED Clinic The practical signal here is not that one route is universally safer, but that route choice clusters with different risk profiles. Tobacco co-use seems to mark a higher-intensity cannabis phenotype, especially for smoking, vaping, and multiple routes, which should prompt more careful counseling about airway exposure, nicotine overlap, and cumulative intoxication. In older adults, oral products are not automatically benign, because delayed onset can lead to redosing and higher total exposure. The absence of associations with depression, distress, or suicidal ideation is reassuring, but it does not remove the need to screen for cannabis use disorder, falls, sedation, and drug interactions in patients over 65. DigestCannabis NewsRegulationPublic HealthClinical Practice AudiencePatients, clinicians, healthcare professionals, regulators, and industry researchers. Primary TopicCurated updates on Cannabis use and route-specific administration amo. Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42800375/) A structured CED Clinic overview of 3 key developments in cannabis regulation, market milestones, and scientific research. What This Study Teaches Us In the 2024 HINTS survey of 6,328 U.S. adults, 23.1% reported past 12-month cannabis use, and more than half of users, 52.7%, used more than one route. Among current tobacco users, cannabis use was 46.0% versus 17.4% in nonusers, and tobacco users who used cannabis were more likely to smoke it (73.4% vs 55.6%), vape it (52.4% vs 32.1%), and use 2 or more routes (60.0% vs 47.9%). In older adults aged 65 and older with past-year cannabis use (N = 1,515), smoking was the most common mode at 66.0%, ingested forms were 42.1%, and smoking and ingested use were associated with higher prevalence of cannabis use disorder, with adjusted prevalence ratios of 3.99 and 1.46, respectively. Why This Matters These data point to a clinically important co-use pattern, tobacco use tracks with more frequent inhaled cannabis exposure and more multi-route use, which can raise respiratory and dependence-related risks. In older adults, the association between smoking or oral cannabis and cannabis use disorder supports routine screening for use pattern, dose escalation, and functional impact, not just whether cannabis is being used at all. Study SnapshotPost TypeCannabis News and Regulatory Roundup using canonical CED layoutItems Reviewed3 verified updatesPrimary DatesSeptember 27, 2026Related Reading3 verified live CED Clinic internal linksStudy 1Cannabis use and route-specific administ (Wilsnack et al., PubMed) [DOI: 10.1016/j.addbeh.2026.108868 | PMID: 42800375]Study 2Modes of Cannabis Use and Mental Health (Jagasia et al., PubMed) [DOI: 10.1111/jgs.70748 | PMID: 42799588]Study 3Industrial Hemp and Tobacco as Multipurp (Varga et al., PubMed) [DOI: 10.3390/plants15182888 | PMID: 42796919] Clinical Bottom Line This cannabis news and regulatory roundup preserves key signals across 3 updates without overstatement, offering grounded guidance for patients and practitioners. Digest Contents - [Digest Card 1 | Cannabis use and route-specific administration amo](#digest-card-2-digest-card-1-cannabis-use-and-route-specific-administration-amo) - [Digest Card 2 | Modes of Cannabis Use and Mental Health Outcomes A](#digest-card-3-digest-card-2-modes-of-cannabis-use-and-mental-health-outcomes-a) - [Digest Card 3 | Industrial Hemp and Tobacco as Multipurpose Crops:](#digest-card-4-digest-card-3-industrial-hemp-and-tobacco-as-multipurpose-crops) Why These 3 Updates Belong Together This curated cannabis news and regulatory roundup brings together 3 key developments across policy, market milestones, and health regulations. Analyzing these distinct updates in one structured overview clarifies emerging patterns while respecting the specific boundaries of each report. Rather than overextending any single announcement or preliminary finding into an oversized headline, grouping verified updates enables readers and clinicians to track the broader direction of the field with precision. Digest Card 1 | Cannabis use and route-specific administration amo **Title & Source:** [Cannabis use and route-specific administration among U.S. adults who do and do not use tobacco: Findings from the 2024 Health Information National Trends Survey.](https://pubmed.ncbi.nlm.nih.gov/42800375/) (*PubMed*, 2026Sep25) **Lead Authors & Identifiers:** Catherine Wilsnack, Laurel P Gibson, Joseph T Ciccolo, Youn Ok Lee, Rachel Grana Mayne, Annette R Kaufman. | **Primary Record:** DOI: 10.1016/j.addbeh.2026.108868 | PMID: 42800375 Content lane: **Evidence Check**. **1. Scientific & Clinical Background:** This was a nationally representative analysis of the 2024 Health Information National Trends Survey, including 6,328 U.S. adults. It examined past 12-month cannabis use and route-specific administration by current tobacco use status. **2. Detailed Findings & Primary Data:** An estimated 23.1% of U.S. adults reported past-year cannabis use, and 52.7% of users reported more than one route. Cannabis use was 46.0% among current tobacco users versus 17.4% among nonusers, and among cannabis users, tobacco users were more likely to smoke cannabis (73.4% vs 55.6%), vape it (52.4% vs 32.1%), and use 2 or more routes (60.0% vs 47.9%). **3. Dr. Caplan’s Clinical & Practical Guidance:** Tobacco use should trigger a more detailed cannabis history, especially around inhaled products and multi-route use. Patients who use both substances may need counseling focused on airway exposure, nicotine overlap, and cumulative intoxication risk. **4. Study Boundaries & Methodological Limits:** This is cross-sectional survey data, so it cannot establish directionality or causation. All exposure measures were self-reported, and the study cannot fully capture potency, dose, or frequency. Digest Card 2 | Modes of Cannabis Use and Mental Health Outcomes A **Title & Source:** [Modes of Cannabis Use and Mental Health Outcomes Among Older Adults in the United States.](https://pubmed.ncbi.nlm.nih.gov/42799588/) (*PubMed*, 2026Sep26) **Lead Authors & Identifiers:** Krish Jagasia, Tyler A Simi, Anderson Lai, Alexandra Z Tien-Smith, Annie L Nguyen, Alison A Moore, Kevin H Yang, Joseph J Palamar. | **Primary Record:** DOI: 10.1111/jgs.70748 | PMID: 42799588 Content lane: **Evidence Check**. **1. Scientific & Clinical Background:** This pooled analysis used 2022 to 2024 National Survey on Drug Use and Health data from 1,515 U.S. adults aged 65 and older with past-year cannabis use. It compared smoking, ingested forms, inhaled concentrates, and other routes with mental health outcomes and cannabis use disorder. **2. Detailed Findings & Primary Data:** Smoking was the most common mode at 66.0%, followed by ingested forms at 42.1%, inhaled concentrates at 17.1%, and other routes at 16.8%. Smoking was associated with higher prevalence of cannabis use disorder (aPR 3.99, 95% CI 1.92 to 8.28), and ingested forms were also associated with CUD (aPR 1.46, 95% CI 1.03 to 2.09), while no mode was associated with major depressive episode, serious psychological distress, or suicidal ideation. **3. Dr. Caplan’s Clinical & Practical Guidance:** Older adults using cannabis should be screened for CUD even when they report oral products rather than smoking. The lack of a mental health signal should not reduce attention to sedation, falls, delayed onset, and medication interactions. **4. Study Boundaries & Methodological Limits:** This remains an observational survey analysis, so residual confounding is likely, especially from pain, sleep problems, and other reasons for use. The mental health outcomes were broad and may miss more subtle cognitive or functional harms. Digest Card 3 | Industrial Hemp and Tobacco as Multipurpose Crops: **Title & Source:** [Industrial Hemp and Tobacco as Multipurpose Crops: Traditional Uses, Contemporary Applications, and Future Perspectives.](https://pubmed.ncbi.nlm.nih.gov/42796919/) (*PubMed*, 2026Sep21) **Lead Authors & Identifiers:** Ivana Varga, Marinka Andraković, Patricia Crljić, Marta Đaković, Manda Antunović, Monika Tkalec Kojić, Dejan Agić. | **Primary Record:** DOI: 10.3390/plants15182888 | PMID: 42796919 Content lane: **Safety Signal**. **1. Scientific & Clinical Background:** This was a narrative review comparing industrial hemp and tobacco as multipurpose crops, with attention to bioactive compounds, health implications, and socio-economic and environmental roles. It contrasts hemp’s expanding industrial applications with tobacco’s persistent health burden. **2. Detailed Findings & Primary Data:** The review describes hemp as a source of fibers, food, cosmetics, pharmaceuticals, and construction materials, with cannabinoids, terpenes, and antioxidant phenolics supporting its bio-based uses. Tobacco is described as nicotine-dominant, with research centered on addiction and toxic constituents, and the paper notes that hemp products still require strict quality control because of variability and possible THC contamination. **3. Dr. Caplan’s Clinical & Practical Guidance:** This paper is most useful for policy and product-context discussions, not bedside efficacy claims. Clinicians should remember that hemp-derived products are not automatically standardized or THC-free, which matters when patients assume they are using a low-risk alternative. **4. Study Boundaries & Methodological Limits:** This is a review, not a primary outcomes study, so it does not provide new clinical effect estimates. The conclusions depend on the quality and scope of the underlying literature, which is not quantified here. How Strong Is This Evidence? The first two papers use large, nationally representative U.S. survey datasets, which strengthens generalizability for prevalence estimates and broad associations. The older-adult analysis includes 1,515 past-year users and adjusts for survey year, demographics, cannabis frequency, and other substance use, while the HINTS analysis adjusts for legality and sociodemographics, giving the findings moderate observational strength. The hemp and tobacco paper is a narrative review, useful for context but much weaker for causal inference. Where This Paper Deserves Skepticism All three papers are limited by design in different ways. The survey studies are cross-sectional, rely on self-report, and cannot determine whether tobacco use drives cannabis route choice or whether heavier cannabis users are more likely to use tobacco, while the older-adult study may still have residual confounding from pain, insomnia, or underlying illness. The hemp and tobacco review is broad and descriptive, with no pooled effect estimates or systematic methods detailed here, so its conclusions are more interpretive than empirical. What This Paper Does Not Show These papers do not prove that smoking or ingesting cannabis causes cannabis use disorder, depression, or any other mental health outcome. They also do not establish that hemp products are clinically effective or that tobacco and cannabis co-use directly worsens long-term health outcomes, only that these patterns are common and clinically relevant. How This Fits With the Broader Clinical Conversation These findings fit with a broader shift in cannabis medicine toward route-specific counseling, because inhaled, oral, and multi-route use can produce very different onset times, peak effects, and adverse event profiles. They also mirror the larger regulatory split between hemp and tobacco, where hemp is increasingly framed as an industrial and bio-based crop, while tobacco remains a high-harm product that often co-travels with cannabis exposure in real-world use. Dr. Caplan’s Take *What stands out most is how often cannabis use is layered onto tobacco use, and how often people are using more than one cannabis route at the same time. That matters because the route is not a trivial detail, it changes onset, duration, intoxication risk, and the chance that someone keeps redosing before the first dose has fully declared itself. When tobacco is in the picture, I think about more than lungs, I think about dependence patterns and whether the patient is actually trying to manage symptoms or simply chasing a faster effect.* *In older adults, I pay close attention to oral products and smoking because both can quietly create trouble. Oral cannabis can look gentle on paper, but delayed absorption often leads to extra dosing, and smoking adds airway burden on top of that. The lack of a signal for depression or suicidal ideation is useful, but it should not be mistaken for safety. The real job is to ask about frequency, route, and function, then match the conversation to the patient’s age, comorbidities, and other substances.* What a Careful Reader Should Take Away Ask not just whether a patient uses cannabis, but how they use it, what else they use, and whether the pattern suggests escalating exposure or dependence. Route-specific counseling and routine screening for cannabis use disorder are the most actionable lessons here. Evidence Interpretation Guide Table of Contents - [How to Interpret This Cannabis News and Regulatory Roundup](#How_to_Interpret_This_Cannabis_News_and_Regulatory_Roundup)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Viewpoints on These Updates](#CED_Perspective_Lens_Eight_Viewpoints_on_These_Updates)[What this means for patients](#What_this_means_for_patients) - [What to ask in clinic](#What_to_ask_in_clinic) - [Safety signals and harm reduction](#Safety_signals_and_harm_reduction) - [Regulatory and public health context](#Regulatory_and_public_health_context) - [What the evidence can and cannot answer](#What_the_evidence_can_and_cannot_answer) - [Where to be cautious](#Where_to_be_cautious) - [What families should watch for](#What_families_should_watch_for) - [Bottom line](#Bottom_line) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Interpret This Cannabis News and Regulatory Roundup These papers are most useful when read as route-of-use studies, not as broad claims about cannabis being good or bad. The key clinical question is how tobacco co-use, age, and delivery method change exposure, dependence risk, and counseling needs. ### Three Rules for Critical Reading **1. Separate prevalence from causation**The HINTS and NSDUH studies show who is using cannabis, how they are using it, and which patterns cluster together, but they do not prove one route causes another outcome. A prevalence ratio of 3.99 for cannabis use disorder in older smokers is important, yet it still sits inside a cross-sectional survey. **2. Treat route as a clinical variable**Smoking, vaping, dabbing, and oral use are not interchangeable. In these studies, tobacco users were more likely to smoke, vape, and use multiple routes, and older adults using smoking or ingested forms had higher CUD prevalence, so route should be part of every cannabis history. **3. Do not overread the absence of mental health associations**The older-adult study found no association between mode and depression, distress, or suicidal ideation, but that does not mean cannabis is psychiatrically neutral. It means this dataset did not detect a mode-specific signal after adjustment, which still leaves room for dose effects, vulnerable subgroups, and unmeasured confounding. Key Evaluation Question Did the study measure route-specific cannabis exposure well enough to distinguish heavier, more frequent, or more complex use patterns from simple yes or no cannabis use? The Patient Question If I use cannabis, what route, dose, and frequency are safest for my age, tobacco use, and other medications? The Bottom Line These studies support route-specific screening and counseling, not blanket assumptions about cannabis safety or harm. CED Perspective Lens ## CED Perspective Lens: Eight Viewpoints on These Updates Why these developments matter across clinical, patient, safety, and policy perspectives Lens OverviewEight distinct clinical and regulatory perspectives on Cannabis use and route-specific administratio. #### What this means for patients If you use cannabis and tobacco together, the pattern matters. In the national survey, nearly half of tobacco users reported cannabis use, and they were more likely to smoke, vape, and use multiple cannabis routes, which can make effects less predictable and increase the chance of overuse. For older adults, oral products are not automatically safer just because they are not smoked. Delayed onset can lead to extra dosing, and the study in adults 65 and older found higher cannabis use disorder prevalence with smoking and ingested forms. Lens takeawayTell your clinician exactly how you use cannabis, not just whether you use it. #### What to ask in clinic These studies support a route-specific cannabis history, especially in patients who use tobacco or are over 65. Ask about smoking, vaping, dabbing, edibles, topicals, and whether more than one route is being used, because multi-route use was common in the national survey. In older adults, screen for cannabis use disorder even if the patient says they only use edibles or pills. The absence of a detected association with depression or suicidal ideation should not replace routine assessment of sedation, falls, cognition, and drug interactions. Lens takeawayRoute, frequency, and co-use should be part of every cannabis assessment. #### Safety signals and harm reduction The strongest safety signal here is not a specific psychiatric harm, it is exposure complexity. Tobacco co-use was linked to more smoking, more vaping, and more multi-route cannabis use, which can increase airway irritation and make intoxication harder to predict. For older adults, oral cannabis may still contribute to dependence and functional impairment. A careful plan should include lower starting doses, slower titration, and explicit counseling against redosing too quickly after an edible. Ongoing observation across diverse patient groups provides essential clarity on how these findings hold up over extended timeframes. Lens takeawayMore routes usually mean more room for dosing mistakes and adverse effects. #### Regulatory and public health context The hemp review highlights a growing policy divide, hemp is increasingly framed as a bio-based industrial crop, while tobacco remains tightly regulated because of established harm. That distinction matters because patients often assume hemp-derived products are standardized or risk-free when they are not. The survey findings also support surveillance that tracks route-specific cannabis use, not just prevalence. Public health systems need better data on inhaled versus oral products, especially where tobacco and cannabis co-use overlap. Lens takeawayRegulation should follow product risk, quality control, and real-world use patterns. #### What the evidence can and cannot answer These are useful observational signals, but they are not causal proof. The HINTS and NSDUH studies can show associations between tobacco, route, and cannabis use disorder, yet they cannot fully separate cause from selection effects or shared risk factors. Future work should measure dose, potency, timing, and reasons for use, especially in older adults and in people who use tobacco. That is where the next clinically meaningful answers will come from. Ongoing observation across diverse patient groups provides essential clarity on how these findings hold up over extended timeframes. Lens takeawayBetter exposure measurement is the next step, not broader speculation. #### Where to be cautious Self-report and cross-sectional design limit confidence in the direction of effect. People who already use more cannabis may be more likely to smoke or use multiple routes, so the association with tobacco may reflect heavier use rather than a tobacco-driven shift in behavior. The older-adult study did not find associations with depression, distress, or suicidal ideation, but that could reflect limited power for specific subgroups or imperfect measurement of mental health burden. A null result is not the same as proof of no risk. Lens takeawayThese findings are real, but they are not the final word on harm. #### What families should watch for Caregivers should pay attention to route changes, especially when an older adult starts using edibles, pills, or multiple products. Delayed effects can lead to accidental overuse, confusion, sedation, or falls, particularly when other medications are already in the mix. If tobacco is also present, the chance of more frequent inhaled cannabis use goes up. That combination should prompt a conversation about respiratory symptoms, dependence, and whether the person is using cannabis for symptom relief or simply escalating use. Lens takeawayWatch for redosing, confusion, falls, and hidden tobacco co-use. to help evaluate realistic outcomes and safe next steps. #### Bottom line The most actionable message is that cannabis use is not one thing, and route matters. Tobacco co-use is linked to more inhaled and multi-route cannabis use, while in older adults smoking and ingested forms are associated with higher cannabis use disorder prevalence. That should push clinicians toward more specific screening, more careful dosing conversations, and less assumption that any non-smoked product is automatically low risk. Ongoing observation across diverse patient groups provides essential clarity on how these findings hold up over extended timeframes. Lens takeawayAsk how, how often, and with what else cannabis is being used. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Cannabis+News+and+Regulatory+Roundup%3A+Cannabis+use+and+route-specific+administrati...&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-news-and-regulatory-roundup-cannabis-use-and-route-specific-adm-sep-2026%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-news-and-regulatory-roundup-cannabis-use-and-route-specific-adm-sep-2026%2F) [BlueSky](https://bsky.app/intent/compose?text=Cannabis+News+and+Regulatory+Roundup%3A+Cannabis+use+and+route-specific+administrati...%20https%3A%2F%2Fcedclinic.com%2Fcannabis-news-and-regulatory-roundup-cannabis-use-and-route-specific-adm-sep-2026%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Sources: PubMed, PubMed, PubMed](https://pubmed.ncbi.nlm.nih.gov/42800375/) Related Reading at CED ClinicContinue exploring the evidence[Cannabis Use Disorder Is Rising Among US Adults](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/) More on this topic: Epidemiological evaluation of diagnostic trends, screening tools, and evidence-based patient counseling. [More on this topic: CUD trends & screening](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/)[The Multifaceted Impact of CBD on Sleep: A Comprehensive Guide for Better Rest](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/) More on this topic: Clinical insights into sleep architecture, circadian rhythm modulation, and cannabinoid titration for insomnia. [More on this topic: Cannabinoids & sleep](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/)[NY Times Response: Teens and Strong Cannabis](https://cedclinic.com/high-potency-cannabis-risks/) More on this topic: Critical discussion of high-potency THC products, youth exposure risks, and clinical communication with teens. [More on this topic: Youth & potency risks](https://cedclinic.com/high-potency-cannabis-risks/) ## Frequently Asked Questions What is covered in this cannabis news and regulatory roundup? This edition reviews 3 verified developments across cannabis policy, regulatory oversight, and clinical science. How are stories selected for CED digests? Stories are curated from official primary sources, government agency dockets, and peer-reviewed journals, focusing on practical relevance for patients and clinicians. Do preliminary reports establish medical efficacy? No. Observational reports, preprints, and regulatory filings describe emerging trends and require formal clinical trials before treatment efficacy can be claimed. How should clinicians use these updates? Clinicians can use these updates to understand patient questions, stay current with state regulations, and maintain evidence-informed counseling. Where can readers find Dr. Caplan's clinical insights? Dr. Caplan provides comprehensive clinical perspectives, patient consultations, and educational resources at CEDclinic.com. Why are multi-topic digests published instead of single stories? Digests group related updates together to provide a broader thematic overview while preserving important nuances and methodological limits. What is the primary role of laboratory testing in cannabis policy? Laboratory testing verifies cannabinoid potency and screens for harmful contaminants like heavy metals, pesticides, and molds to protect consumer health. How do state regulatory milestones impact patient access? Administrative milestones establish the licensing rules, product categories, and retail standards that determine how and where registered patients obtain care. What precautions should families take with medical cannabis at home? Families should keep all medical cannabis products securely locked in child-resistant containers and clearly labeled to avoid accidental exposure. How often does CED Clinic publish clinical and policy updates? CED Clinic publishes regular morning, afternoon, and evening evidence reviews and news digests to keep the community informed. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).